Alix Ventures
VC Fund
San Francisco, United States
Alix Ventures is a VC fund in San Francisco focused on Health Care and Biotechnology. Alix Ventures: Driving Patient Impact - Supporting Early Stage Life Science Startups Engineering Biology to Drive Radical Advances in Human HealthBorn from our collective experience as founders, we set out to build the fund we wanted to raise from...Thesis: Life Sciences is experiencing rapid innovation with the rise of TechBio, a change webelieve is leading to some of the most impactful solutions in decades. Our passion is to help build transformative companies ahead of this revolution to significantly impact the quality & effectiveness of patient care. We aim to partner with passionate, accomplished founders who possess unique insights to solve some of the world’s most daring problems facing us in Life Sciences.Team: Our entire team is composed of serial VC backed Life Sciences founders with experience in raising capital, scaling teams, running labs, navigating regulatory mazes, partnering with pharma & the many fires that consist of operating an early stage company. We’ve been in your shoes before, we pride ourselves in being the VC we wish we had on our own cap tables, founders we are here to help! SAB/MAB: Composed of top VC-backed PhD Life Sciences founders, our scientific & medical advisory board aids our investment team in both technical & clinical diligence - thus providing a multitude of expertise & fluency across a wide variety of Life Science sub-domains. Let’s talk science!Support: Helping our founders is our utmost priority. To tackle the many challenges ahead, we’ve curated a full platform of resources to help with customer introductions, fundraising, & team building, amongst others. In addition, dedicated to supporting our portfolio is our operating partner - Mark Pulido (5x HC/LS CEO - previously of Novartis, McKesson, & Ability) & our extensive network of industry executives spanning Top 25 Pharma, major health systems, & large payors.Limited Partners: Anchored by leading strategic LPs making up some of the best venture capital firms in the world, veteran founders, & industry experts. Alix is here to fill the void for early stage Life Sciences specific capital in Silicon Valley.
- Total investments:
- 24
- Last investment:
- Lead investor:
- 13%
Last updated:
For AI agents: llms.txt
Industries Alix Ventures invests in
Stages Alix Ventures invests in
Countries Alix Ventures invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Seed
- $2M–$12M
- Pre-Seed
- $2.7M–$2.7M
- Series A
- $12M–$70M
Investment Focus
Industry
- Health Care 8 (33%)
- Biotechnology 8 (33%)
- Life Science 6 (25%)
- Medical 5 (21%)
- Biopharma 3 (13%)
Stage
- Seed 8 (33%)
- Series A 7 (29%)
- Pre-Seed 3 (13%)
- Series B 1 (4%)
- Funding Round 1 (4%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Chas Pulido
Founder and General Partner
|
Founder and General Partner | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Italic Health, Inc. is a healthcare technology company building a unified platform for managing patient data, medical billing, and insurance workflows. Its software integrates health records, appointment scheduling, and AI-driven analytics to improve care coordination, financial processes, and patient engagement. | Seed / Jan 01, 2026 | ||
| iOrganBio is a pioneering cell production platform that uses CellForge to facilitate the intelligent manufacturing of human cells and organoids. | $2M / Seed / Oct 29, 2025 | ||
| Galatea Bio, a US-based biotechnology company was founder by Carlos Bustamante, Nicholas Katsanis and Alexander Ioannidis. Our mission is to drive groundbreaking discoveries in healthcare by pairing genetic diversity with cutting-edge data analytics. Our passion is fueled by a focus on populations historically underrepresented in genetics research.We achieve this by leveraging our world-class clinical network and biobank, cutting-edge algorithms, and innovative analyses to discover and validate new tests, treatments, and cures that will improve the lives of all. | $8M / Venture - Series Unknown / Mar 27, 2025 | ||
| Elegen is a biotechnology company that develops microfluidic technology. It is driven by a mission to deploy this technology in a new generation of DNA synthesizers aimed at enabling and accelerating biomedical advances. The company was founded in 2017 and led by Dr. Matthew Hill. | $35M / Series B / May 14, 2024 | ||
| Zafrens specializes in developing tools and generating insights at the interface of biology, chemistry, and engineering. The company was founded in 2021 and is headquartered in San Diego, California, United States. | $23M / Series A / Dec 11, 2023 | ||
| Digitising Chemistry and Chemical Discovery | $47.1M / Series A / Aug 02, 2023 | ||
| Xilis is an oncology and precision health company that diagnoses cancer and finds the right treatment. The company uses “micro-organoids” to make thousands of 3D replicas of a patient’s tumor in about six days, which the company says can be used for testing for drug compatibility faster. It was founded in 2019 and is headquartered in Durham,North Carolina. | $19M / Series A / Jul 13, 2022 | ||
| Endpoint Health is a precision immunology company that is breaking the efficacy barrier of traditional pharma's “one-size-fits-all” drug development strategy by developing precision therapies with outsized efficacy potential in autoimmune and inflammatory conditions. They’re accomplishing this by leveraging OMNAI, their proprietary AI-poweredpatient discovery platform, to identify and match high-potential therapies to the patients most likely to respond. | $52M / Series A / Jun 02, 2022 | ||
| A comprehensive platform and product suite for advanced therapeutics. | $55M / Series A / Jan 19, 2022 | ||
| Zafrens specializes in developing tools and generating insights at the interface of biology, chemistry, and engineering. The company was founded in 2021 and is headquartered in San Diego, California, United States. | $6M / Seed / Dec 27, 2021 | ||
| See all 24 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Featured in Investor Lists
Recommended lists
FAQ
What does Alix Ventures invest in?
Alix Ventures invests primarily in Health Care, Biotechnology and Life Science startups, most often at Seed and Series A stage. Most of the 24 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Alix Ventures's check size?
Alix Ventures typically joins rounds of $2M–$12M at Seed, $2.7M–$2.7M at Pre-Seed and $12M–$70M at Series A. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Alix Ventures participates in.
How do I contact Alix Ventures?
Public channels for Alix Ventures include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Alix Ventures?
The team at Alix Ventures includes Chas Pulido (Founder and General Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
